论文部分内容阅读
目的研究大剂量盐酸氨溴索(沐舒坦)对重度急性呼吸窘迫综合征(ARDS)患者的疗效。方法重度ARDS患者40例,随机分成对照组和试验组,各20例。两组患者常规治疗的同时,对照组每天给予生理盐水20 ml静脉推注q.6 h,试验组每天给予生理盐水20 ml加沐舒坦150 mg静脉推注q.6 h,连续应用7 d。比较两组患者在治疗前及治疗7 d后急性生理评分(APACHEⅡ)、肺顺应性、氧合指数的差异及ICU停留时间。结果相比对照组,试验组患者7 d后的APACHEⅡ、氧合指数、肺顺应性有明显改善,ICU停留时间缩短,差异有统计学意义(P<0.05)。结论大剂量沐舒坦可以改善重度ARDS患者肺顺应性,提高氧合,缩短ICU住院时间。
Objective To investigate the efficacy of ambroxol hydrochloride in patients with severe acute respiratory distress syndrome (ARDS). Methods Forty patients with severe ARDS were randomly divided into control group and trial group, with 20 cases in each group. The two groups of patients with conventional treatment at the same time, the control group were given daily intravenous injection of 20 ml saline q.6 h, the experimental group were given daily saline 20 ml plus mucosolvan 150 mg intravenously q.6 h, continuous application of 7 d. The differences of acute physiology score (APACHEⅡ), lung compliance, oxygenation index and ICU stay before and 7 days after treatment were compared between the two groups. Results Compared with the control group, the APACHE Ⅱ, oxygenation index and lung compliance of the experimental group were significantly improved after 7 days, and the ICU stay time was shortened (P <0.05). Conclusions High-dose ambroxol can improve pulmonary compliance in patients with severe ARDS, improve oxygenation and shorten the hospital stay of ICU.